Topical mineralocorticoid receptor blockade limits glucocorticoid-induced epidermal atrophy in human skin

Journal of Investigative Dermatology

Volumn 135, Issue 7, 2015, Pages 1781-1789

  Maubec, Eve ^a,b   Laouénan, Cédric ^a,b,c   Deschamps, Lydia ^a   Nguyen, Van Tuan ^d,e   Scheer Senyarich, Isabelle ^a   Wackenheim Jacobs, Anne Catherine ^a   Steff, Maud ^a,b   Duhamel, Stéphanie ^e,f   Tubiana, Sarah ^a,b,c   Brahimi, Nesrine ^a   Leclerc Mercier, Stéphanie ^g   Crickx, Béatrice ^a,b   Perret, Claudine ^e,f   Aractingi, Selim ^b,h   Escoubet, Brigitte ^a,b,f   Duval, Xavier ^a,b,c   Arnaud, Philippe ^a,b,i,j   Jaisser, Frederic ^e,f   Mentré, France ^a,b,c   Farman, Nicolette ^e,f  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

^d CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h Institut Cochin   (France)

ⁱ CNRS   (France)

^j INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANRENOIC ACID; CLOBETASOL; EPITHELIAL SODIUM CHANNEL; MINERALOCORTICOID RECEPTOR; PHENAMIL; PLACEBO; SPIRONOLACTONE; GLUCOCORTICOID; MINERALOCORTICOID ANTAGONIST;

ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPIDERMIS; FOREARM; GEL; HUMAN; HUMAN TISSUE; KERATINOCYTE; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SKIN ATROPHY; ADULT; ATROPHY; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; EPILUMINESCENCE MICROSCOPY; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEEDLE BIOPSY; NONPARAMETRIC TEST; NORMAL HUMAN; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROCEDURES; REFERENCE VALUE; RISK ASSESSMENT; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, TOPICAL; ADULT; ATROPHY; BIOPSY, NEEDLE; CLOBETASOL; DERMOSCOPY; DOUBLE-BLIND METHOD; EPIDERMIS; FEMALE; GLUCOCORTICOIDS; HEALTHY VOLUNTEERS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID; REFERENCE VALUES; RISK ASSESSMENT; SPIRONOLACTONE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84931063566     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.44     Document Type: Article

References (47)

1. Bender SB, McGraw AP, Jaffe IZ, et al. (2013) Mineralocorticoid receptormediated vascular insulin resistance: an early contributor to diabetesrelated vascular disease?. Diabetes 62:313-9
2. Brouard M, Casado M, Djelidi S, et al. (1999) Epithelial sodium channel in human epidermal keratinocytes: expression of its subunits and relation to sodium transport and differentiation. J Cell Sci 112: 3343-52
3. Cossmann M, Welzel J. (2006) Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial. Br J Dermatol 155:700-6
4. De Bosscher K, Haegeman G, Elewaut D. (2010) Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 10: 497-504
5. Fagart J, Hillisch A, Huyet J, et al. (2010) A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 285:29932-40
6. Farman N, Maubec E, Poeggeler B, et al. (2010) The mineralocorticoid receptor as a novel player in skin biology: beyond the renal horizon?. Exp Dermatol 19:100-7
7. Farman N, Rafestin-Oblin ME. (2001) Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol 280:F181-92
8. Gomez-Sanchez CE, de Rodriguez AF, Romero DG, et al. (2006) Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology 147:1343-8
9. Gross KL, Cidlowski JA. (2008) Tissue-specific glucocorticoid action: a family affair. Trends Endocrinol Metab 19:331-9
10. Guder G, Bauersachs J, Frantz S, et al. (2007) Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115:1754-61
11. Guitard M, Leyvraz C, Hummler E. (2004) A nonconventional look at ionic fluxes in the skin: lessons from genetically modified mice. News Physiol Sci 19:75-9
12. Guo C, Martinez-Vasquez D, Mendez GP, et al. (2006) Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 147:5363-73
13. Ito N, Ito T, Kromminga A, et al. (2005) Human hair follicles display a functional equivalent of the hypothalamic-pituitary-Adrenal axis and synthesize cortisol. FASEB J 19:1332-4
14. Kenouch S, Lombes M, Delahaye F, et al. (1994) Human skin as target for aldosterone: coexpression of mineralocorticoid receptors and 11 betahydroxysteroid dehydrogenase. J Clin Endocrinol Metab 79:1334-41
15. Kolkhof P, Borden SA. (2012) Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 350:310-7
16. Leopold JA. (2011) Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling. Circulation 124:e466-8
17. Maron BA, Leopold JA. (2010) Aldosterone receptor antagonists: effective but often forgotten. Circulation 121:934-9
18. Mauro T, Guitard M, Behne M, et al. (2002) The ENaC channel is required for normal epidermal differentiation. J Invest Dermatol 118:589-94
19. Mihailidou AS, Loan Le TY, Mardini M, et al. (2009) Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 54:1306-12
20. Milik E, Szczepanska-Sadowska E, Maslinski W, et al. (2007) Enhanced expression of mineralocorticoid receptors in the heart after the myocardial infarct in rats. J Physiol Pharmacol 58:745-55
21. Mitts TF, Bunda S, Wang Y, et al. (2010) Aldosterone and mineralocorticoid receptor antagonists modulate elastin and collagen deposition in human skin. J Invest Dermatol 130:2396-406
22. Nagase T, Akase T, Sanada H, et al. (2013) Aging-like skin changes in metabolic syndrome model mice are mediated by mineralocorticoid receptor signaling. Aging Cell 12:50-7
23. Nguyen Dinh Cat A, Jaisser F (2012) Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens 21:147-56
24. Perez P. (2011) Glucocorticoid receptors, epidermal homeostasis and hair follicle differentiation. Dermatoendocrinol 3:166-74
25. Pitt B, Remme W, Zannad F, et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-21
26. Pitt B, Zannad F, Remme WJ, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-17
27. Rhen T, Cidlowski JA. (2005) Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 353:1711-23
28. Sainte Marie Y, Toulon A, Paus R, et al. (2007) Targeted skin overexpression of the mineralocorticoid receptor in mice causes epidermal atrophy, premature skin barrier formation, eye abnormalities, and alopecia. Am J Pathol 171:846-60
29. Schacke H, Berger M, Rehwinkel H, et al. (2007) Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 275:109-17
30. Schacke H, Schottelius A, Docke WD, et al. (2004) Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 101:227-32
31. Schoepe S, Schacke H, May E, et al. (2006) Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 15:406-20
32. Shavit L, Lifschitz MD, Epstein M. (2012) Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 81:955-68
33. Slominski A, Ermak G, Mihm M. (1996) ACTH receptor, CYP11A1, CYP17 and CYP21A2 genes are expressed in skin. J Clin Endocrinol Metab 81:2746-9
34. Slominski A, Gomez-Sanchez CE, Foecking MF, et al. (1999) Metabolism of progesterone to DOC, corticosterone and 18OHDOC in cultured human melanoma cells. FEBS Lett 455:364-6
35. Slominski A, Zbytek B, Nikolakis G, et al. (2013a) Steroidogenesis in the skin: implications for local immune functions. J Steroid Biochem Mol Biol 137: 107-23
36. Slominski A, Zbytek B, Semak I, et al. (2005a) CRH stimulates POMC activity and corticosterone production in dermal fibroblasts. J Neuroimmunol 162: 97-102
37. Slominski A, Zbytek B, Szczesniewski A, et al. (2005b) CRH stimulation of corticosteroids production in melanocytes is mediated by ACTH. Am J Physiol Endocrinol Metab 288:E701-6
38. Slominski A, Zbytek B, Szczesniewski A, et al. (2006) Cultured human dermal fibroblasts do produce cortisol. J Invest Dermatol 126:1177-8
39. Slominski A, Zjawiony J, Wortsman J, et al. (2004) A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin. Eur J Biochem 271:4178-88
40. Slominski AT, Manna PR, Tuckey RC. (2014) Cutaneous glucocorticosteroidogenesis: securing local homeostasis and the skin integrity. Exp Dermatol 23:369-74
41. Slominski AT, Zmijewski MA, Zbytek B, et al. (2013b) Key role of CRF in the skin stress response system. Endocr Rev 34:827-84
42. Soundararajan R, Pearce D, Hughey RP, et al. (2010) Role of epithelial sodium channels and their regulators in hypertension. J Biol Chem 285:30363-9
43. Takeda M, Tatsumi T, Matsunaga S, et al. (2007) Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11betahydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens Res 30:427-37
44. Walton S, Cunliffe WJ, Lookingbill P, et al. (1986) Lack of effect of topical spironolactone on sebum excretion. Br J Dermatol 114:261-4
45. Zennaro MC, Caprio M, Feve B (2009) Mineralocorticoid receptors in the metabolic syndrome. Trends Endocrinol Metab 20:444-51
46. Zhao M, Celerier I, Bousquet E, et al. (2012) Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 122: 2672-9
47. Zoller NN, Kippenberger S, Thaci D, et al. (2008) Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-Thickness skin model. Toxicol In Vitro 22:747-59